These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 35239201

  • 1. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J, Flammer AJ, Palazzuoli A, Barragan PM, Thum T, Marcos MC, Miró Ò, Rossignol P, Metra M, Lassus J, Orso F, Jankowska EA, Chioncel O, Milicic D, Hill L, Seferovic P, Rosano G, Coats A, Damman K.
    Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
    [Abstract] [Full Text] [Related]

  • 2. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice.
    Savarese G, Lindberg F, Christodorescu RM, Ferrini M, Kumler T, Toutoutzas K, Dattilo G, Bayes-Genis A, Moura B, Amir O, Petrie MC, Seferovic P, Chioncel O, Metra M, Coats AJS, Rosano GMC.
    Eur J Heart Fail; 2024 Jun; 26(6):1408-1418. PubMed ID: 38515385
    [Abstract] [Full Text] [Related]

  • 3. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B, Zhang R, Wu X, Zhou X.
    JAMA Netw Open; 2022 Sep 01; 5(9):e2231963. PubMed ID: 36125813
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD.
    Lancet; 2020 Jul 11; 396(10244):121-128. PubMed ID: 32446323
    [Abstract] [Full Text] [Related]

  • 6. Indian Consensus on the Role and Position of Angiotensin Receptor-neprilysin Inhibitors in the Management of Heart Failure.
    Chopra HK, Ponde C, Wander GS, Nair T, Ray S, Khullar D, Nanda NC, Narula J, Kasliwal RR, Rana DS, Kirpalani A, Sawhney JS, Chandra P, Mehta Y, Kumar V, Tiwari S, Pancholia AK, Kher V, Bansal S, Mittal S, Kerkar P, Sahoo PK, Hotchandani R, Prakash S, Chauhan N, Rastogi V, Abdullakutty J, Shanmugasundaram S, Tiwaskar M, Sinha A, Gupta V, Mishra SS, Routray SN, Omar AK, Swami OC, Jaswal A, Alam S, Passey R, Rajput R, Paul J, Kapoor A, Dorairaj P, Chandra S, Malhotra P, Singh VP, Bansal M, Jain S, Shah P, Bhargava M, Vijayalakshmi IB, Varghaese K, Jain D, Goel A, Mahmood K, Gaur N, Tandon R, Moorthy A, George S, Katyal VK, Mantri RR, Mehrotra R, Bhalla D, Mittal V, Rao S, Jagia M, Singh H, Awasthi S, Sattur A, Mishra R, Pandey A, Chawla R, Jaggi S, Sehgal B, Sehgal A, Goel N, Gupta R, Kubba S, Chhabra A, Bagga S, Shastry RN.
    J Assoc Physicians India; 2024 Sep 11; 72(9):75-82. PubMed ID: 39291524
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.
    Hellenkamp K, Nolte K, von Haehling S.
    Expert Opin Pharmacother; 2022 Apr 11; 23(6):673-680. PubMed ID: 35260016
    [Abstract] [Full Text] [Related]

  • 8. Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey.
    Fauvel C, Bonnet G, Mullens W, Giraldo CIS, Mežnar AZ, Barasa A, Tokmakova M, Shchendrygina A, Costa FM, Mapelli M, Zemrak F, Tops LF, Jakus N, Sultan A, Bahouth F, Hadjseyd CE, Salvat M, Anselmino M, Messroghli D, Weberndörfer V, Giverts I, Bochaton T, Courand PY, Berthelot E, Legallois D, Beauvais F, Bauer F, Lamblin N, Damy T, Girerd N, Sebbag L, Pezel T, Cohen-Solal A, Rosano G, Roubille F, Mewton N.
    Eur J Heart Fail; 2023 Feb 11; 25(2):213-222. PubMed ID: 36404398
    [Abstract] [Full Text] [Related]

  • 9. [A practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection fraction].
    Soltani S, Böhm M, Frey N, Eden M, Abdin A, Bauersachs J.
    Dtsch Med Wochenschr; 2022 Jul 11; 147(14):931-938. PubMed ID: 35868319
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New pharmacotherapy for heart failure with reduced ejection fraction.
    Sotirakos S, Wheen P, Spiers J, Armstrong R.
    Expert Rev Cardiovasc Ther; 2020 Jul 11; 18(7):405-414. PubMed ID: 32546023
    [Abstract] [Full Text] [Related]

  • 12. [European guidelines on heart failure: pharmacotherapy].
    Grundmann S, von Zur Mühlen C.
    Herz; 2023 Mar 11; 48(2):89-94. PubMed ID: 36695878
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
    Yan BW, Spahillari A, Pandya A.
    Circ Cardiovasc Qual Outcomes; 2023 Jun 11; 16(6):e009793. PubMed ID: 37278232
    [Abstract] [Full Text] [Related]

  • 15. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
    Mareev YV, Mareev VY.
    Kardiologiia; 2021 Jul 01; 61(6):4-10. PubMed ID: 34311683
    [Abstract] [Full Text] [Related]

  • 16. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
    Abdelhamid M, Rosano G, Metra M, Adamopoulos S, Böhm M, Chioncel O, Filippatos G, Jankowska EA, Lopatin Y, Lund L, Milicic D, Moura B, Ben Gal T, Ristic A, Rakisheva A, Savarese G, Mullens W, Piepoli M, Bayes-Genis A, Thum T, Anker SD, Seferovic P, Coats AJS.
    Eur J Heart Fail; 2022 Sep 01; 24(9):1460-1466. PubMed ID: 35753058
    [Abstract] [Full Text] [Related]

  • 17. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
    Malgie J, Clephas PRD, Brunner-La Rocca HP, de Boer RA, Brugts JJ.
    Heart Fail Rev; 2023 Sep 01; 28(5):1221-1234. PubMed ID: 37311917
    [Abstract] [Full Text] [Related]

  • 18. Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC.
    Christodorescu R, Geavlete O, Ferrini M, Kümler T, Toutoutzas K, Bayes-Genis A, Seferovic P, Metra M, Chioncel O, Rosano GMC, Savarese G.
    Eur J Heart Fail; 2024 Sep 24. PubMed ID: 39318024
    [Abstract] [Full Text] [Related]

  • 19. The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice.
    Bánfi-Bacsárdi F, Muk B, Pilecky D, Duray GZ, Kiss RG, Nyolczas N.
    Cardiology; 2023 Sep 24; 148(1):27-37. PubMed ID: 36470212
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study.
    Jensen J, Poulsen MK, Petersen PW, Gerdes B, Rossing K, Schou M.
    ESC Heart Fail; 2023 Jun 24; 10(3):1745-1756. PubMed ID: 36852608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.